Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Tokyo's benchmark Nikkei 225 index has dipped more than 4% and most other markets in Asia also sank after a retreat on Wall ...

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

Stocks fell in afternoon trading on Wall Street Tuesday, pulled down by losses in the same big tech companies that have been ...

The bidding war over biotechnology company Metsera (MTSR) has intensified, drawing fierce competition from pharmaceutical ...

The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to ...

Dow Jones Top Company Headlines at 7 PM ET: AMD Reports Sharply Higher Profits, Sales | IBM ... The chip maker reported steep gains in both profit and sales for the third quarter as it moved deeper ...

Revenue was down 5.9% from last year to $16.654, after increasing 10% the previous quarter. These results were better than ...

The battle for control of a promising obesity drug maker has intensified, with one pharmaceutical giant upping its bid to $10 ...

Denmark's Novo Nordisk said Tuesday it would replace more than half of its board, including the chair, as the Ozempic and Wegovy maker restructures in the face of rising competition for its ...